Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Abstract #233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program

    Endocrine Practice Date published:

  • Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

    Cardiovascular Diabetology Date published:

  • Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

    European Heart Journal Date published:

  • Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

    Diabetes, Obesity and Metabolism Date published:

  • Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology

    Kidney International Supplements Date published:

  • Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

    Circulation Date published:

  • Associations between body mass index and the risk of renal events in patients with type 2 diabetes

    Nutrition & Diabetes Date published:

  • Effects of the DPP-4 Inhibitor Linagliptin on Heart Failure Outcomes in Patients With Type 2 Diabetes and Cardio-Renal Disease in CARMELINA

    Date published:

  • Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease

    Date published:

  • Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration

    Hypertension: A Companion to Braunwald's Heart Disease Date published:

  • Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration

    Hypertension: A Companion to Braunwald's Heart Disease Date published:

  • The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

    American Journal of Nephrology Date published:

  • Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    New England Journal of Medicine Date published:

  • Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON

    Diabetes Care Date published:

  • Action plan for optimizing the design of clinical trials in chronic kidney disease

    Kidney International Supplements Date published:

  • Closing the gap between evidence and practice in chronic kidney disease

    Kidney International Supplements Date published: